Adaptimmune Therapeutics Plc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.12
- Today's High:
- $1.2
- Open Price:
- $1.2
- 52W Low:
- $1.01
- 52W High:
- $2.65
- Prev. Close:
- $1.2
- Volume:
- 963900
Company Statistics
- Market Cap.:
- $196.59 million
- Book Value:
- 0.498
- Revenue TTM:
- $27.15 million
- Operating Margin TTM:
- -603.97%
- Gross Profit TTM:
- $27.15 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.67%
- Return on Equity TTM:
- -114.97%
Company Profile
Adaptimmune Therapeutics Plc had its IPO on 2015-05-06 under the ticker symbol ADAP.
The company operates in the Healthcare sector and Biotechnology industry. Adaptimmune Therapeutics Plc has a staff strength of 494 employees.
Stock update
Shares of Adaptimmune Therapeutics Plc opened at $1.2 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.12 - $1.2, and closed at $1.12.
This is a -6.67% slip from the previous day's closing price.
A total volume of 963,900 shares were traded at the close of the day’s session.
In the last one week, shares of Adaptimmune Therapeutics Plc have slipped by -5.88%.
Adaptimmune Therapeutics Plc's Key Ratios
Adaptimmune Therapeutics Plc has a market cap of $196.59 million, indicating a price to book ratio of 1.9948 and a price to sales ratio of 11.7708.
In the last 12-months Adaptimmune Therapeutics Plc’s revenue was $27.15 million with a gross profit of $27.15 million and an EBITDA of $-157890000. The EBITDA ratio measures Adaptimmune Therapeutics Plc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Adaptimmune Therapeutics Plc’s operating margin was -603.97% while its return on assets stood at -25.67% with a return of equity of -114.97%.
In Q4, Adaptimmune Therapeutics Plc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 678.3%.
Adaptimmune Therapeutics Plc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0.11
Its diluted EPS in the last 12-months stands at $-0.81 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.11. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adaptimmune Therapeutics Plc’s profitability.
Adaptimmune Therapeutics Plc stock is trading at a EV to sales ratio of 2.7835 and a EV to EBITDA ratio of -0.2826. Its price to sales ratio in the trailing 12-months stood at 11.7708.
Adaptimmune Therapeutics Plc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $328.92 million
- Total Liabilities
- $64.50 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $3.18 million
- Dividend Payout Ratio
- 0%
Adaptimmune Therapeutics Plc ended 2023 with $328.92 million in total assets and $0 in total liabilities. Its intangible assets were valued at $328.92 million while shareholder equity stood at $81.88 million.
Adaptimmune Therapeutics Plc ended 2023 with $0 in deferred long-term liabilities, $64.50 million in other current liabilities, 1399000.00 in common stock, $-909302000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $108.03 million and cash and short-term investments were $204.61 million. The company’s total short-term debt was $2,728,000 while long-term debt stood at $0.
Adaptimmune Therapeutics Plc’s total current assets stands at $255.37 million while long-term investments were $0 and short-term investments were $96.57 million. Its net receivables were $7.44 million compared to accounts payable of $4.75 million and inventory worth $0.
In 2023, Adaptimmune Therapeutics Plc's operating cash flow was $0 while its capital expenditure stood at $3.18 million.
Comparatively, Adaptimmune Therapeutics Plc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.12
- 52-Week High
- $2.65
- 52-Week Low
- $1.01
- Analyst Target Price
- $5.88
Adaptimmune Therapeutics Plc stock is currently trading at $1.12 per share. It touched a 52-week high of $2.65 and a 52-week low of $2.65. Analysts tracking the stock have a 12-month average target price of $5.88.
Its 50-day moving average was $1.63 and 200-day moving average was $1.69 The short ratio stood at 10.28 indicating a short percent outstanding of 0%.
Around 12% of the company’s stock are held by insiders while 7077.9% are held by institutions.
Frequently Asked Questions About Adaptimmune Therapeutics Plc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company’s specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.